Rocatinlimab achieved a 32.8% EASI-75 response at week 24, but fell short of market leader Dupixent’s results. Uplizna improved MG-ADL and QMG scores significantly, offering potential as a treatment ...
A new study has said that people who took certain dietary supplements in the form of multivitamin tablets, were as likely to develop depression as those who took placebo pills. Consumption of energy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback